Q-omics provides the consensus-scored HTR3A profile across patient tissues and cancer cell-line models. HTR3A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, HTR3A is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, HTR3A RNA expression shows 10,907 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where HTR3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTR3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTR3A survival associations across molecular data types. HTR3A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTR3A RNA expression–survival associations across cancer types. High HTR3A expression shows unfavorable associations in KIRC, UCEC, LUAD and LIHC, but favorable associations in HNSC and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for HTR3A RNA expression.
This table summarizes HTR3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HTR3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTR3A shows lower tumor expression in COAD, HNSC and READ and higher tumor expression in LUAD, KIRP and LUSC. The COAD box plot shows higher HTR3A RNA expression in normal versus tumor tissue (log2 FC = −1.291, t-test p < 0.001).
This table shows molecular features associated with HTR3A in patient tissues and cancer cell lines. In patient samples, HTR3A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HTR3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_NSCLC_LUAD.
